ALC
Alcon AG
NYSE: ALC · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$62.56
+0.35% today
Updated 2026-06-05
Market cap
$33.11B
P/E ratio
40.66
P/S ratio
3.11x
EPS (TTM)
$1.67
Dividend yield
0.53%
52W range
$62 – $92
Volume
2.0M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
4.7
Growth
C6.8
Quality
B4.5
Profitability
C3.3
Valuation
D3/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$89.38
+42.87%
12-Month target
$59.27
-5.26%
Intrinsic (DCF)
$64.04
Margin of safety
-23.97%
5 Strong Buy17 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $273.58M — positive
+ Debt/equity 0.24x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- 23.97% above intrinsic value
- P/E 40.66x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $8.72B | $9.46B | $9.91B | $10.40B | $10.63B | $11.2B |
| Net income | $335.00M | $974.00M | $1.02B | $980.00M | $185.33M | — |
| EPS | — | — | — | — | $1.67 | $3.40 |
| Free cash flow | $472.00M | $537.00M | $1.41B | $1.73B | $273.58M | — |
| Profit margin | 3.84% | 10.30% | 10.27% | 9.42% | 7.70% | — |
Peer comparison
Smart narrative
Alcon AG trades at $62.56. representing a P/E of 40.66x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. TTM revenue stands at $10.63B. with profit margins at 7.70%. Our DCF model estimates intrinsic value at $64.04.
Frequently asked questions
What is Alcon AG's stock price?
Alcon AG (ALC) trades at $62.56, on a P/E of 40.7x and a P/S of 3.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Alcon AG overvalued?
Alcon AG carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $64.04 against the $62.56 price, so on cash flow terms the market is paying a premium for Alcon AG's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Alcon AG (ALC)?
The 12-month analyst consensus target is $89.38, about 42.9% above the current $62.56. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of ALC by 2030?
Our research-backed model puts the 2030 base case at $335.52, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Alcon AG (ALC)?
Our DCF model estimates intrinsic value at $64.04, a -24.0% margin of safety versus today's $62.56. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Alcon AG's revenue?
Alcon AG's trailing twelve-month revenue is $10.63B, and our model projects it reaching about $14.07B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.11x
ROE3.66%
Beta0.70
50D MA$71.33
200D MA$76.62
Shares out0.49B
Float0.49B
Short ratio—
Avg volume2.0M
Performance
1 week+0.00%
1 month+4.98%
3 months-12.58%
YTD-15.23%
1 year—
3 years—
5 years—